Serdexmethylphenidate/dexmethylphenidate

Serdexmethylphenidate/dexmethylphenidate, sold under the brand name Azstarys, is a fixed-dose combination medication containing serdexmethylphenidate and dexmethylphenidate which is used to treat attention deficit hyperactivity disorder (ADHD) in people aged six years and older.[2][3]

Not to be confused with serdexmethylphenidate.

Serdexmethylphenidate/dexmethylphenidate
Combination of
SerdexmethylphenidateProdrug of dexmethylphenidate
DexmethylphenidateCatecholamine reuptake inhibitor
Clinical data
Trade namesAzstarys
Other namesKP415
AHFS/Drugs.comMicromedex Detailed Consumer Information
License data
Routes of
administration		By mouth
ATC code
  • None
Legal status
Legal status
  • US: Schedule II [1]
Identifiers
KEGG

It was approved for medical use in the United States in March 2021.[2]

References
  1. "Azstarys- serdexmethylphenidate and dexmethylphenidate capsule". DailyMed. Archived from the original on 13 July 2021. Retrieved 13 July 2021.
  2. "KemPharm Announces FDA Approval of Azstarys (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD" (Press release). KemPharm. 3 March 2021. Archived from the original on 3 March 2021. Retrieved 3 March 2021 – via GlobeNewswire.
  3. McCuistion LE, Yeager JJ, Winton MB, DiMaggio K (2021). "Chapter 18: Stimulants". Pharmacology E-Book: A Patient-Centered Nursing Process Approach. St. Louis, MO: Elsevier Health Sciences. p. 203. ISBN 978-0-323-79316-2. Archived from the original on 9 January 2022. Retrieved 9 January 2022.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.